Endovascular Treatment of Haemodialysis Arteriovenous Fistula with Drug-Coated Balloon Angioplasty: A Single-Centre Study

Lučev, Jernej; Breznik, Silva; Dinevski, Dejan; Ekart, Robert; Rupreht, Mitja

doi:10.1007/s00270-018-1942-z

Cited by 26 publications

(26 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…retrospective study [21], a prospective study [22], and a prospective cohort [23]. Second, the number of censored cases during follow-up was not provided in some of the studies.…”

Section: Plos Onementioning

confidence: 99%

Drug-coated balloon versus conventional balloon angioplasty of hemodialysis arteriovenous fistula or graft: A systematic review and meta-analysis of randomized controlled trials

et al. 2020

View full text Add to dashboard Cite

Background Restenosis remains a significant problem in endovascular therapy for hemodialysis vascular access. Drug-coated balloon (DCB) angioplasty decreases restenosis in peripheral and coronary artery diseases. The aim of this systematic review and meta-analysis is to assess the patency outcomes following DCB angioplasty, as compared to conventional balloon (CB) angioplasty for the stenosis of hemodialysis vascular access. Methods A comprehensive search in the MEDLINE, EMBASE, and CENTRAL databases was conducted in order to identify eligible randomized controlled trials evaluating DCB angioplasty for hemodialysis vascular access dysfunction. The primary endpoint was the 6-month target lesion primary patency and the secondary endpoints were 12-month target lesion primary patency and procedure-related complications. Risk ratios (RR) were pooled and relevant subgroups were analyzed separately. Results Eleven randomized controlled trials comprised of 487 patients treated with DCB angioplasty and 489 patients treated with CB angioplasty were included. There were no significant

show abstract

“…retrospective study [21], a prospective study [22], and a prospective cohort [23]. Second, the number of censored cases during follow-up was not provided in some of the studies.…”

Section: Plos Onementioning

confidence: 99%

Drug-coated balloon versus conventional balloon angioplasty of hemodialysis arteriovenous fistula or graft: A systematic review and meta-analysis of randomized controlled trials

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In another retrospective comparative study, Lučev et al ( 24 ) reported that TLPP was significantly higher in the DBA group than the PBA group at 6 months (90.3% vs. 61.3%; p = 0.016), 12 months (77.4% vs. 29.0%; p = 0.0004), and 24 months (45.2% vs. 16.1%; p = 0.026). In a recent prospective RCT comparing DBA and PBA groups, Irani et al ( 17 ) reported a TLPP of 81% and 61% ( p = 0.03) at 6 months, and 51% and 34% ( p = 0.04) at 12 months, respectively.…”

Section: Discussionmentioning

confidence: 96%

“…To date, multiple observational and randomized controlled studies have evaluated the use of DCBs for prolonging patency, but caution should be taken when interpreting the results due to clinical heterogeneity resulting from the non-uniform level of intervention ( 8 9 11 12 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 ). In a retrospective study in 2014, Patanè et al ( 9 ) presented a case series of 26 patients who had juxta-anastomotic radiocephalic stenosis treated using DBA.…”

Section: Discussionmentioning

confidence: 99%

Paclitaxel-Coated Balloon versus Plain Balloon Angioplasty for Dysfunctional Autogenous Radiocephalic Arteriovenous Fistulas: A Prospective Randomized Controlled Trial

Kim

Byun

et al. 2020

Korean J Radiol

View full text Add to dashboard Cite

Objective To report the mid-term results of a single-center randomized controlled trial comparing drug-coated balloon angioplasty (DBA) and plain balloon angioplasty (PBA) for the treatment of dysfunctional radiocephalic arteriovenous fistulas (RCAVFs). Materials and Methods In this prospective study, 39 patients (mean age, 62.2 years; 21 males, 18 females) with RCAVFs failing due to juxta-anastomotic stenosis were randomly assigned to undergo either both DBA and PBA (n = 20, DBA group) or PBA alone (n = 19, PBA group) between June 2016 and June 2018. Primary endpoints were technical and clinical success and target lesion primary patency (TLPP); secondary outcomes were target lesion secondary patency (TLSP) and complication rates. Statistical analysis was performed using the Kaplan-Meier product limit estimator. Results Demographic data and baseline clinical characteristics were comparable between the groups. Technical and clinical success rates were 100% in both groups. There was no significant difference between the groups in the mean duration of TLPP (DBA group: 26.7 ± 3.6 months; PBA group: 27.0 ± 3.8 months; p = 0.902) and TLSP (DBA group: 37.3 ± 2.6 months; PBA group: 40.4 ± 1.5 months; p = 0.585). No procedural or post-procedural complications were identified. Conclusion Paclitaxel-coated balloon use did not significantly improve TLPP or TLSP in the treatment of juxta-anastomotic stenosis of dysfunctional RCAVFs.

show abstract

“…30 In a randomized study including 40 patients with stenotic venous outflow lesions who underwent either DCB-PTA (n = 20) or PB-PTA (n = 20), Katsanos et al 31 reported that the cumulative TLPP rate was significantly higher in the DCB-PTA group than the PB-PTA group at 6 months (70% vs 25%; p < 0.001; hazard ratio (HR): 0.30, 95% confidence interval (CI): 0.12-0.71; p < 0.006). Lucev et al 32 also evaluated the effect of PTA on AVF combined with either DCB or PB vessel preparation and found that the TLPP rate was significantly higher in the DCB group than the PB group at 6 months (90.3% vs 61.3%; p = 0.016), at 12 months (77.4% vs 29%; p = 0.0004), and at 24 months (45.2% vs 16.1%; p = 0.026). In another study, two brands of DCB versus PB were compared in patients with juxta-anastomotic stenosis of mature but failing distal radiocephalic AVFs and all patients treated with DCB-PTA had statistically significantly higher primary patency, TLPP, secondary patency, and target lesion secondary patency rates.…”

Section: Discussionmentioning

confidence: 99%

A retrospective comparison analysis of results of drug-coated balloon versus plain balloon angioplasty in treatment of juxta-anastomotic de novo stenosis of radiocephalic arteriovenous fistulas

et al. 2019

View full text Add to dashboard Cite

Background: Juxta-anastomotic stenosis is a common issue of arteriovenous fistulas. We aimed to evaluate the results of percutaneous transluminal angioplasty with drug-coated balloon versus plain balloon for the treatment of juxta-anastomotic stenoses of mature but failing distal radiocephalic arteriovenous fistulas. Methods: A total of 80 patients with a juxta-anastomotic stenosis of distal radiocephalic arteriovenous fistula in our clinic between January 2016 and September 2017 were retrospectively analyzed. Patients were divided into two groups according to the type of treatment as drug-coated balloon – percutaneous transluminal angioplasty (n = 44) and plain balloon – percutaneous transluminal angioplasty (n = 43). Intra- and post-procedural data were recorded. Target lesion primary patency rate was evaluated at 6 and 12 months. Of all patients, 48 were females and 39 were males with a mean age of 56.3 ± 10.4 (range, 24–75) years. Both groups had mature fistulas, and the mean age of fistula was 11.3 ± 9.1 months in the drug-coated balloon – percutaneous transluminal angioplasty group and 10.3 ± 8.8 months in the plain balloon – percutaneous transluminal angioplasty group (p = 0.24). Results: There was no significant difference in the target lesion stenosis rate and the median lesion length between the groups. Technical and clinical success were achieved in both groups. Target lesion primary patency was similar at 6 months between the two groups (93.1% vs 81.3%, respectively; p = 0.14) but significantly higher for the drug-coated balloon – percutaneous transluminal angioplasty group at 12 months (81.8% vs 51.1%, respectively; p = 0.01). Conclusion: Our study results suggest that the use of drug-coated balloon combined with percutaneous transluminal angioplasty is an effective treatment for juxta-anastomotic stenoses of mature but failing distal radiocephalic arteriovenous fistulas with significantly improved target lesion primary patency rates and reduced need for juxta-anastomotic reinterventions.

show abstract

Endovascular Treatment of Haemodialysis Arteriovenous Fistula with Drug-Coated Balloon Angioplasty: A Single-Centre Study

Abstract: DCB increases target lesion primary patency during the first 24 months and decreases the rate of reinterventions.

Cited by 26 publications

References 39 publications

Drug-coated balloon versus conventional balloon angioplasty of hemodialysis arteriovenous fistula or graft: A systematic review and meta-analysis of randomized controlled trials

Drug-coated balloon versus conventional balloon angioplasty of hemodialysis arteriovenous fistula or graft: A systematic review and meta-analysis of randomized controlled trials

Paclitaxel-Coated Balloon versus Plain Balloon Angioplasty for Dysfunctional Autogenous Radiocephalic Arteriovenous Fistulas: A Prospective Randomized Controlled Trial

A retrospective comparison analysis of results of drug-coated balloon versus plain balloon angioplasty in treatment of juxta-anastomotic de novo stenosis of radiocephalic arteriovenous fistulas

Contact Info

Product

Resources

About